MYC and neuroblastoma: Using Myc inhibition in conjunction with, or in place of Doxorubicin, treatments could potentially improve the prognoses of children with high-risk Neuroblastoma and decrease the opportunity for relapse driven by mesenchymal cancer cell proliferation.